Schrödinger, Inc. (43Z)
XSTU 
Summary
43Z Chart
Wall Street Analysts Believe Schrodinger (SDGR) Could Rally 46.17%: Here's is How to Trade
The consensus price target hints at a 46.2% upside potential for Schrodinger (SDGR). While empirical research shows that this sought-after metric is hardly effective, an upward trend in earnings estimate revisions could mean that the stock will witness an upside in the near term.
Here's Why Schrodinger (SDGR) Is a Great 'Buy the Bottom' Stock Now
Schrodinger (SDGR) witnesses a hammer chart pattern, indicating support found by the stock after losing some value lately. This coupled with an upward trend in earnings estimate revisions could mean a trend reversal for the stock in the near term.
Schrödinger, Inc. (SDGR) Q3 2025 Earnings Call Transcript
Schrödinger, Inc. ( SDGR ) Q3 2025 Earnings Call November 5, 2025 4:30 PM EST Company Participants Jaren Madden - Chief Corporate Affairs Officer & Head of Investor Relations Ramy Farid - CEO, President & Director Richie Jain - Executive VP, CFO & Treasurer Karen Akinsanya - President, Head of Therapeutics R&D and Chief Strategy Officer & Partnerships Conference Call Participants Mani Foroohar - Leerink Partners LLC, Research Division Scott Schoenhaus - KeyBanc Capital Markets Inc., Research Division Matthew Hewitt - Craig-Hallum Capital Group LLC, Research Division Conor MacKay - BMO Capital Markets Equity Research Dennis Ding Brendan Smith - TD Cowen, Research Division Michael Ryskin - BofA Securities, Research Division Presentation Operator Thank you for standing by. Welcome to Schrodinger's conference call to review third quarter 2025 financial results.
Schrödinger, Inc. (43Z) FAQ
What is the stock price today?
On which exchange is it traded?
What is its stock symbol?
Does it pay dividends? What is the current yield?
What is its market cap?
When is the next earnings date?
Has Schrödinger, Inc. ever had a stock split?
Schrödinger, Inc. Profile
| Pharmaceuticals Industry | Healthcare Sector | Ramy Farid CEO | XSTU Exchange | US80810D1037 ISIN |
| US Country | 891 Employees | - Last Dividend | - Last Split | 6 Feb 2020 IPO Date |
Overview
Schrödinger, Inc. is a pioneering company that develops a sophisticated computational platform grounded in physics, which is designed for the discovery of novel molecules applicable in both drug development and materials science. Since its inception in 1990, Schrödinger has been operating out of New York, New York, undertaking ambitious endeavors in molecular discovery across two primary segments: Software and Drug Discovery. The Software segment is dedicated to revolutionizing molecular discovery in the life sciences and materials science industries through its proprietary software solutions. On the flip side, the Drug Discovery segment is committed to advancing a broad spectrum of preclinical and clinical programs either internally or in partnership with other entities. Catering to a global clientele, Schrödinger serves a wide range of industries, including biopharmaceutical firms, industrial companies, academic institutions, and government laboratories around the world.
Products and Services
- Software Licensing
Under the Software segment, Schrödinger offers licenses for its cutting-edge software designed to significantly enhance the process of molecular discovery. This software is strategically crafted for both life sciences and materials science sectors, streamlining and expediting the research and development process for a myriad of applications.
- Drug Discovery
In the Drug Discovery segment, Schrödinger emphasizes the development of a diversified portfolio of drug candidates. This portfolio spans various stages of the discovery and development process, ranging from preclinical studies to clinical trials. The company not only works on these programs internally but also collaborates with external partners to leverage collective expertise and resources, thereby fostering innovation and accelerating the journey of potential drugs from the laboratory to the marketplace.
